Arya Mehrabanzad - Profile and Investment Details

Investor Profile

Arya Mehrabanzad is a Venture Capital, Private Equity Firm based in Boston, Massachusetts, United States with a diverse investment portfolio that includes companies such as Blackstone Technology Group, Detector Technology, Dynex Technologies, New England Peptide, LightPointe, Adaptas Solutions, Leinco Technologies, MedPharm, AnaBios CorporationCoreLab Partners, CRI Lifetree, N2 Biomedical LLC, Agilux Laboratories, Silicon Wave, ALPCO Diagnostics, GenDx, ProGene Biomedical, Cequent Pharmaceuticals, ACLARA BioSciences, TriPath Imaging, FirstRain, Proficiency, Vibalogics, NanoImaging Services, Brammer Bio, Corpus Medical, GeneWerk, Bioventus, Magritek Ltd, Chantest, LakePharma, Magellan Diagnostics, Innovative Food Processors, Signature Genomic Laboratories, Endeca, Viracor-IBT Laboratories, Panacos Pharmaceuticals, vivitide, Confluent Medical Technologies, Viadux, Talecris Biotherapeutics, RadPharm, Canopy Biosciences, Nitinol Devices & Components, Azurity Pharmaceuticals, Sanova Dermatology, Ensemble Communications, BioClinica, MedVenture Technology, Ortho Organizers, Nexelis, Interpace Diagnostics, Assay Designs, NutraMed, Roadrunner Pharmacy, Avista Pharma, Blue Sky Biotech, Alcami, Medifacts International, Elite One Source Nutritional Services, Genome Diagnostics (GenDx), BioEcho Life Sciences, GENEWIZ, Arranta Bio, Stereotaxis, Bako Diagnostics, ETE Medical Inc, StageBio, Cyclis Pharmaceuticals, Nexcelom Bioscience, Genoptix, . Over time, Arya Mehrabanzad has demonstrated experience in supporting a range of businesses across various sectors.

While it is not publicly confirmed whether Arya Mehrabanzad is currently seeking new investment opportunities, their past investments provide valuable insight into the types of projects and industries that have attracted their attention.

Startups and entrepreneurs operating in sectors related to Health Care, Telecommunications, Drug Discovery, Genetics, Wellness, Women Founded, Enterprise Software, Investment Management, Healthcare Innovation, Life Science, Portfolio Management, Medical Technologies, Genetic Testing, Information Technology (IT), Bioinformatics, Software, Manufacturing, Biotechnology, Healthcare IT, Medical Devices, Drug Development, Specialty Pharma, Genomics, Precision Medicine, Innovation, Clinical Trials, Gene Therapy, Consulting, Medical Diagnostics, Health Diagnostics, Market Intelligence, Regulatory Compliance, Medical, Information Technology, B2B, Therapeutics, Molecular Diagnostics, Media and Entertainment, Pharmaceuticals, Healthcare Technology may find it worthwhile to explore potential connections with Arya Mehrabanzad, as their portfolio suggests a familiarity and interest in this area.

Understanding Arya Mehrabanzad’s investment history can offer useful context for founders considering outreach and help identify whether there is a potential fit based on strategic alignment and market focus.